Medium-term response characterisation and risk factor analysis of botulinum toxin type A in the management of spasticity in children with cerebral palsy

European Journal of Neurology

Volumn 6, Issue SUPPL. 4, 1999, Pages s37-s45

  Boyd, Roslyn N ^a   Graham, Judith E A ^a   Nattrass, Gary R ^a   Graham, H Kerr ^a  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

Botulinum toxin; Cerebral palsy; Gait analysis; Outcome; Risk factors

Indexed keywords

BOTULINUM TOXIN A;

ADOLESCENT; ADULT; BIOMECHANICS; BOTULISM; CEREBRAL PALSY; CHILD; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; GAIT; HEMATOMA; HUMAN; INCONTINENCE; KINETICS; MAJOR CLINICAL STUDY; MUSCLE FUNCTION; MUSCLE LENGTH; MUSCLE WEAKNESS; PAIN; PEDIATRIC SURGERY; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RATING SCALE; RISK FACTOR; SOFT TISSUE; SPASTICITY;

EID: 0033396968     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1331.1999.tb00033.x     Document Type: Conference Paper

References (41)

1. Abbot R (1992). Complications with selective posterior rhizotomy. Pediatr Neurosurg 18:43-47.
2. Albright AL (1996). Baclofen in the treatment of cerebral palsy. J Child Neurol 11:77-88.
3. Albright AL, Barron WB, Fasick MP, Polinko P, Janosky J (1993). Continuous intrathecal baclofen infusion for spasticity of cerebral origin. J Am Med Assoc 270:2475-2477.
4. Anderson T, Rivest J, Stell R, Steiger MJ, Cohen H, Thompson PD, Marsden CD (1992). Botulinum toxin treatment of spasmodic torticollis. J R Soc Med 85:524-529.
5. Baillieu C, Barwood S, Boyd RN, Graham HK (1997). The analgesic effects of botulinum toxin a in adductor release surgery in children with cerebral palsy: a pilot study [Abstract]. Dev Med Child Neurol 39 (suppl 75): PD12.
6. Biglan A, Gonnering R, Lockhart L, Rabin B, Fuerste F (1986). Absence of antibody production in patients treated with botulinum A toxin. Am J Ophthalmol 101:232-235.
7. Bohannon RW, Smith MB (1987). Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 67:206-207.
8. Boscarino LF, Ounpuu S, Davis RB, Gage JR, De Luca PA. (1993). Effects of selective posterior rhizotomy on gait in children with cerebral palsy. J Pediatr Orthopaedics 13.174-179.
9. Boyd RN, Britton T, Robinson R, Borzyskowski M (1996). Transient urinary incontinence after botulinum A toxin. Lancet 348:481-482.
10. Boyd RN, Graham HK (1997). Botulinum toxin A in the management of children with cerebral palsy: indications and outcome. Eur J Neurol 4 (suppl 2): 15-22.
11. Boyd RN, Pliatsios V, Starr R, Nattrass G, Graham HK (1997). Biomechanical transformation of the gastrosoleus muscle by injection of botulinum toxin A and casting in ambulant children with cerebral palsy [Abstract]. Dev Med Child Neurol 40 (suppl 75):PD13 (full paper in press Dev Med Child Neurol).
12. Boyd RN, Barwood SA, Ballieu C, Graham HK (1998a). Validity of a clinical measure of spasticity in children with cerebral palsy in a double blinded randomised controlled clinical trial [Abstract]. Dev Med Child Neurol 40 (suppl 78):7.
13. Boyd RN, Pliatsios V, Graham HK (1998b). Use of objective measures in predicting response to botulinum toxin A in children with cerebral palsy. Dev Med Child Neurol 40 (suppl 78):48 (full paper in press Dev Med Child Neurol).
14. Boyd RN, Graham HK (1999). Objective measurement of clinical findings in the use of botulinum toxin type A for the management of children with cerebral palsy. Eur J Neurol 6 (suppl 4):23-35.
15. Boyd RN, Graham HK, Scott O (1999). Botulinum toxin A and muscle contracture in ambulant children with cerebral palsy - a kinematic study. Masters of Science (Physiotherapy) thesis. London, UK: University of East London.
16. Corry I, Cosgrove A, Walsh E, McClean D, Graham H (1997). Botulinum toxin A in the hemiplegic upper limb: a double-blind trial. Dev Med Child Neurol 39:185-193.
17. Corry I, Cosgrove A, Duffy C, McNeil S, Taylor T, Graham H (1998). Botulinum toxin A compared with stretching casts in the treatment of spastic equinus, a randomised prospective trial. J Pediatr Orthopaedics 18:304-311.
18. Cosgrove AP, Graham HK (1994). Botulinum toxin A prevents the development of contractures in the hereditary spastic mouse. Dev Med Child Neurol 36:379-385.
19. Cosgrove AP, Corry IS, Graham HK (1994). Botulinum toxin in the management of the lower limb in cerebral palsy. Dev Med Child Neurol 36:386-396.
20. De Paiva A, Meunier FA, Mologo J, Aoki R, Dolly JO (1999). Functional repair of motor endplates after botulinum neurotoxin type A poisoning: bi-phasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA 96:3200-3205.
21. Dolly JO, Black J, Williams RS, Melling J (1984). Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalisation. Nature 307:457-460.
22. Dolly JO, Ashton AC, McInnes C, Wadsworth JDF, Poulain B, Tqauc L, Shone CC (1990). Clues to the multiplastic inhibitory action of botulinum neurotoxins on release of transmitters. J Physiol 84:237-246.
23. Dolly JO, de Paiva A, Foran P, Lawrence G, Daniels-Holgate P, Ashton AC (1994). Probing the process of transmitter release with botulinum and tetanus neurotoxins. Seminars Neurosci 6:149-158.
24. Eames NWA, Baker R, Hill A, Graham HK, Cosgrove AP, (1999). The effect of Botulinum Toxin A on gastrocnemius muscle length: magnitude & duration of response. Dev Med Child Neurol 41:226-232.
25. Erbyuth F (1992). Botulinum-toxin in cervial dystonia: a three years' experience [Abstract]. Movement Disorders 7:135.
26. Fossberg H, Tedroff G (1997). Botulinum toxin treatment in cerebral palsy: intervention with poor evaluation? Dev Med Child Neurol 39:635-640.
27. Göschel H, Wohlfarth K, Frevert J, Dengler R, Bigalke H (1997). Botulinum A toxin therapy: neutralizing and non-neutralizing antibodies - therapeutic consequences. Exp Neurol 147:96-102.
28. Graham HK, Aoki R, Autti-Ramo I, Boyd RN, Delgado MR, Gaebler-Spira DJ, et al. (1999). Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait Posture (in press).
29. Greene WB, Dietz FR, Goldberg MJ, Gross RH, Miller F, Sussman MD (1991). Rapid progression of hip subluxation in cerebral palsy after selective posterior rhizotomy. J Pediatr Orthopaedics. 11:161-165.
30. Jankovic J, Schwartz K (1993). Longitudinal experience with botulinum toxin injections for the treatment of blepharospasm and cervical dystonia. Neurology 43:834-836.
31. Koman LA, Mooney JF III, Smith BP, Goodman A (1993). Management of cerebral palsy with botulinum toxin A: preliminary investigation. J Pediatr Orthopaedics 13:489-495.
32. Koman LA., Mooney JF III, Smith BP, Goodman A (1994). Management of cerebral palsy with Botulinum toxin. A report of a preliminary randomised, double-blind trial. J Pediatr Orthopaedics 14:229-303.
33. Peter JC, Hoffman EB, Arens LJ, Peacock WJ (1990). Incidence of spinal deformity in children after multiple level laminectomy for selective posterior rhizotomy. Child's Nervous System 6:30-32.
34. Peter JC, Hoffman EB, Arens LJ (1993). Spondylolysis and spondylolisthesis after five-level lumbosacral laminectomy for selective posterior rhizotomy in cerebral palsy. Child's Nervous System 9:285-287.
35. Russell D, Rosenbaum P, Cadman D, Gowland C, Hardy S, Jarvis S (1989). The gross motor function measure: a means to evaluate the effects of physical therapy. Dev Med Child Neurol 31:341-352.
36. Smithson F, Boyd RN, Nattrass G, Graham HK (1999). Hip Surveillance clinic, striving towards best clinical practice. National Australian Paediatric Conference Proceedings. Australian Physiotherapy Association, September 1999.
37. Sutherland D, Kaufman K, Wyatt M, Chambers H (1996). Injection of botulinum A toxin into the gastrocnemius muscle of patients with cerebral palsy: a 3-dimensional motion analysis study. Gait Posture 4:269-279.
38. Sutherland DH, Kaufman K, Wyatt MP, Chambers HG, Muborak SJ (1999). Double-blind study of Botulinum Toxin A injections into the gastrocnemius muscle in patients with cerebral palsy. Gait Posture 10:1-9.
39. Tardieu G, Shentoub S, Delarue R (1954). A la Recherche d'une technique de mesure de la spasticite. Neurologique 91:143-144.
40. Vaughan CL, Subramanian N, Busse ME (1998). Selective dorsal rhizotomy as a treatment option for children with cerebral palsy. Gait Posture 8:43-59.
41. Wyatt MP, Kaufman KR, Mubarak SJ, Sutherland DH (1998). Double blind study of effects on gait of injections into the gastrocnemius muscle in cerebral palsy patients [Abstract]. Gait Posture 7:166.